Document,Word,TFIDFVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications,0.1916566166050265
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,0.1916566166050265
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,58,0.17928572760530784
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,0.15389591938967045
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction,0.1524926843262967
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,0.14158866681337282
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,endpoints,0.13598609849967105
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,0.13598609849967105
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify,0.129937374437487
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed,0.12451930530952214
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,0.20169788664235325
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathology,0.17738199880226907
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,0.17738199880226907
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing,0.16773344949339736
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cavities,0.16729120003530662
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac,0.15770604605704275
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,element,0.15314650241800906
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricle,0.1431106797457844
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,set,0.1235884176721249
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,provides,0.1235884176721249
Physiological Assessment of Coronary Lesions in 2020.,physiology,0.22470467690527712
Physiological Assessment of Coronary Lesions in 2020.,coronary,0.22241594310759571
Physiological Assessment of Coronary Lesions in 2020.,cad,0.19761518275277004
Physiological Assessment of Coronary Lesions in 2020.,physiological,0.15985616520710902
Physiological Assessment of Coronary Lesions in 2020.,ffr,0.15943468515856277
Physiological Assessment of Coronary Lesions in 2020.,pci,0.15943468515856277
Physiological Assessment of Coronary Lesions in 2020.,invasive,0.14595426651848512
Physiological Assessment of Coronary Lesions in 2020.,intervention,0.13638975728120536
Physiological Assessment of Coronary Lesions in 2020.,assessment,0.12377936309124558
Physiological Assessment of Coronary Lesions in 2020.,practice,0.12290933864112769
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management,0.298263111006963
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,0.298263111006963
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,0.2771048790265988
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,date,0.23845155354011197
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,editorial,0.23845155354011197
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trialed,0.23845155354011197
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,improvements,0.21829015162245052
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,suggests,0.21829015162245052
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,progress,0.21829015162245052
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,highlights,0.21829015162245052
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base,0.2844192457693743
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,0.22874110990000346
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editors,0.22874110990000346
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,0.20940073914829785
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",editing,0.18454688719617648
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized,0.18454688719617648
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual,0.18454688719617648
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",38,0.14928487415360892
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse,0.1422685147275347
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",brain,0.13633626735941884
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,0.27665983288949647
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,0.19708738410400903
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile,0.19708738410400903
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,infection,0.1812840983097415
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus,0.1812840983097415
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west,0.18042337875437298
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology,0.1686000787996651
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,0.15942921487456305
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host,0.15900886053203292
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animals,0.15900886053203292
Photoplethysmography based atrial fibrillation detection: a review.,af,0.2310672714846182
Photoplethysmography based atrial fibrillation detection: a review.,stroke,0.20321072846145277
Photoplethysmography based atrial fibrillation detection: a review.,ppg,0.17909157119006006
Photoplethysmography based atrial fibrillation detection: a review.,rhythm,0.17909157119006006
Photoplethysmography based atrial fibrillation detection: a review.,devices,0.17112549592248935
Photoplethysmography based atrial fibrillation detection: a review.,detection,0.17112549592248935
Photoplethysmography based atrial fibrillation detection: a review.,sensors,0.16394913620390722
Photoplethysmography based atrial fibrillation detection: a review.,possible,0.16394913620390722
Photoplethysmography based atrial fibrillation detection: a review.,today,0.16394913620390722
Photoplethysmography based atrial fibrillation detection: a review.,wearable,0.13806297261652364
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,0.20844708285117963
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,0.1925894881825691
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",datasets,0.19062193280378445
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,0.17319994447473397
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cytometry,0.15852260462685194
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,0.15852260462685194
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell,0.15839480554651053
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,0.15810464067152222
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,0.15810464067152222
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",course,0.15810464067152222
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,msspe,0.23392778455387853
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enrichment,0.1881338969539761
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic,0.1881338969539761
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral,0.1722269210734983
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viruses,0.1722269210734983
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,0.1649152920293453
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencing,0.160940742075044
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fever,0.15178524347512573
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,0.15178524347512573
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs,0.15178524347512573
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,0.2288816303019887
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,0.21831411065568948
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aecs,0.20405666155824312
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,methylation,0.20405666155824312
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,0.18660695412797365
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,0.18660695412797365
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,0.18660695412797365
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci,0.16411036855491126
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc,0.1509513169602786
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,markers,0.1450673513736081
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,0.2559500505177085
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg,0.23430912697277043
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,signal,0.19255835369782448
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic,0.18160421172635927
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,0.16624932957861385
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,0.16624932957861385
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic,0.1553548673174176
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,glucose,0.1399999851696722
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy,0.1341623299080733
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects,0.1246451030219268
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,0.2509827966279936
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry,0.22231636124402618
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc,0.22231636124402618
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,v10gy,0.20330519331132388
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,0.20330519331132388
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,0.20330519331132388
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose,0.18335996980174843
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage,0.16445896573694652
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,0.16367813030137723
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,0.16367813030137723
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl,0.22164685282722793
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,0.22164685282722793
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,0.20717175219217404
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate,0.2029063111226725
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,0.16661564658951464
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,0.14605272339991932
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal,0.13477981780693618
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tubules,0.13442445457100013
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,0.13442445457100013
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic,0.13442445457100013
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,0.3111052183465959
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,0.26620134912461757
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy,0.26592141494937993
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,0.23386299625285095
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,0.22531914734910738
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life,0.2050007199464514
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain,0.1964526938164729
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,0.1886791928556349
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,0.1886791928556349
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ba,0.1886791928556349
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,0.27706313380761977
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,0.22441559984044065
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,0.22282503621754665
Gated recurrent unit-based heart sound analysis for heart failure screening.,screening,0.19532501327103094
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,0.18012529033413255
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn,0.17977383619979936
Gated recurrent unit-based heart sound analysis for heart failure screening.,frames,0.17977383619979936
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,0.15293725476505213
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,0.14545378253459995
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically,0.14542382654587838
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,0.2722605591289421
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,0.24924055998264819
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgrouping,0.2489784615717124
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroups,0.2189626173456917
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,0.20707833607321954
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein,0.17712467152073236
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,0.1766576609737536
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest,0.16172101639397027
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,quartiles,0.16172101639397027
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,0.15566424886896418
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptl3,0.2526064103259868
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptl4,0.22375453108774981
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,0.204620379456224
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,0.1655228547090822
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,0.16473696803045523
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,0.16473696803045523
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein,0.14546810801520713
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense,0.1451842757566679
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antibodies,0.1451842757566679
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal,0.1451842757566679
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast,0.3163944554557358
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,obesity,0.23690758408595994
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,ikkε,0.2355348231831729
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer,0.20817125315600213
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,inflammation,0.19785708403347657
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages,0.14649395325366485
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,genetic,0.14649395325366485
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pathway,0.1403855154851376
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cc,0.11223360525190468
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,connecting,0.11223360525190468
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived,0.2776287566157082
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,0.24313415214291983
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older,0.23041166810718847
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ubiquity,0.2151376889055653
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,0.18920155243588274
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,anxiety,0.18920155243588274
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies,0.18404136554531667
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults,0.18136000755340198
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,general,0.17320430483789778
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,0.1618540770365825
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary,0.22645681708817467
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviours,0.21663714889645275
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,0.17548396952516446
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,0.1660735674037239
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,countries,0.154328326341491
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive,0.14595209636769343
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,0.14195363955769114
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sub,0.1412796572577418
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,behaviour,0.1412796572577418
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,0.13642039647720927
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,0.25746431146232446
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,0.22481324415192588
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",e2,0.22481324415192588
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",placebo,0.19216217684152737
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,0.18185739879540028
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,0.17525405156175716
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,0.16998082976130494
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",months,0.16199176453343425
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein,0.1554450840255912
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",001,0.13661135988265985
Heart Failure With Mid-range Ejection Fraction.,hfmref,0.2722310102638318
Heart Failure With Mid-range Ejection Fraction.,hfpef,0.2279022580436486
Heart Failure With Mid-range Ejection Fraction.,hfref,0.2279022580436486
Heart Failure With Mid-range Ejection Fraction.,ef,0.21893885298972016
Heart Failure With Mid-range Ejection Fraction.,fraction,0.1808662106416936
Heart Failure With Mid-range Ejection Fraction.,ejection,0.1808662106416936
Heart Failure With Mid-range Ejection Fraction.,range,0.17710544790258062
Heart Failure With Mid-range Ejection Fraction.,pathophysiology,0.16170346455864673
Heart Failure With Mid-range Ejection Fraction.,mid,0.15110689676132621
Heart Failure With Mid-range Ejection Fraction.,failure,0.1443504306158852
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,0.2733138562643216
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,0.2502047994181728
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,0.17734109822534014
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,0.16945288479849227
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index,0.1610899354476385
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,0.1610899354476385
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly,0.1434559202436724
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary,0.13101290273057425
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,0.12993057242125153
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent,0.12171909036793961
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,0.277389355161274
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,0.2577715141321456
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,0.25074118498917075
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,0.2367850912375544
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal,0.2079684345403798
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune,0.1779083659299418
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,responses,0.1779083659299418
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,overlap,0.16823118531000011
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,0.15880975947872486
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell,0.15550509129115786
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal,0.23308938072795032
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,0.22392196592842772
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free,0.20498906032873115
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,progenitors,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,ipsc,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mesenchyme,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,fibrosis,0.1806588321837071
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic,0.1806588321837071
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,0.22230809199681953
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites,0.21356470572044553
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,panel,0.21356470572044553
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,acid,0.1826957437026634
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,bnp,0.17230265986252039
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc,0.17230265986252039
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,0.17230265986252039
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic,0.146581373269487
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable,0.1328293523379042
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,0.12729069483997388
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,0.25010784649744766
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,0.22872011666756648
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,0.19280992697031707
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative,0.18501777164531785
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,0.18413932496615165
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,complementary,0.16228375969982678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,maps,0.16228375969982678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca,0.16228375969982678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator,0.16228375969982678
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular,0.14856244794721948
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,0.2994962847050973
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,0.27595469863808836
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile,0.22353334214751186
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,0.20463329521501827
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating,0.19658505941306748
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac,0.16227136945332904
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,0.15860358813427472
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function,0.15163509798893815
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,050,0.14519343987361155
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,0.14519343987361155
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,0.21760691557086598
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers,0.21755480756753165
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,0.19117185336622958
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,0.18787734410874307
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal,0.1750080141551236
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,0.16898867919940921
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker,0.16353958772325447
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gpc,0.15423624758000282
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modalities,0.15423624758000282
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel,0.14010236439822854
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,0.3073161733703234
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergy,0.2461910528093266
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,0.21065667348350287
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis,0.18506593224832982
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic,0.18506593224832982
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen,0.18506593224832982
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction,0.1694183569403433
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,experience,0.13668566363474932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,0.13668566363474932
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,asthma,0.13668566363474932
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,0.2760869550184661
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis,0.17543816744398938
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implantation,0.17543816744398938
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing,0.16137080584220978
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci,0.16115489961966264
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,001,0.15508069663754015
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,score,0.15378641002794163
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,0.15008007229887313
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,0.1473738947367865
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,95,0.14493013055570886
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,0.24732034806346065
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,icus,0.1604750770360887
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarms,0.1604750770360887
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia,0.14690669185319233
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,units,0.14690669185319233
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false,0.14690669185319233
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed,0.1414047496797961
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,88,0.13727976936052158
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal,0.13727976936052158
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity,0.12981254815020005
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,0.2069798086245624
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,t2dm,0.2069798086245624
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,bp,0.16646127804608188
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north,0.16646127804608188
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose,0.15956221423720637
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,73,0.15238675145739225
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,0.15238675145739225
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,0.15238675145739225
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,china,0.15238675145739225
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,0.14591740629953212
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,0.20792283086599841
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home,0.16428394801191507
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr,0.1502353655916872
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci,0.14322696942653498
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,0.13815627350009932
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression,0.1318519522330073
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,95,0.12880715030741485
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization,0.1285201211249915
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs,0.12729664695580895
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic,0.1266476700437943
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,0.23349606143261817
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs,0.23349606143261817
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,0.20654352964082295
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,0.20534671323957307
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate,0.16567243527364087
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,help,0.15166460641012394
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed,0.15166460641012394
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,tests,0.14172589366413985
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,52,0.14172589366413985
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,recall,0.14172589366413985
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,0.2517039693189716
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization,0.24314511540255035
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,0.24180787096227493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered,0.15265350424547997
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multidisciplinary,0.15265350424547997
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,0.15265350424547997
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,0.1397812608158424
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically,0.1397464436390795
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses,0.1397464436390795
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient,0.1257083490920426
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,0.26548190274432354
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,0.24068052790209585
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,morphology,0.22496239422303846
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave,0.20589220438596778
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,0.18092357850518168
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,offs,0.14596800395049514
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut,0.14596800395049514
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomials,0.14596800395049514
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,0.14596800395049514
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting,0.14596800395049514
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,0.22660126001229988
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,0.1822416186349863
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,0.17727125343824995
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,0.16683284286952638
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,0.16683284286952638
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,0.16639591295531528
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,valsartan,0.15590014247802986
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,0.15308901998163352
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registries,0.147031390428166
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx,0.147031390428166
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,0.2395027730135476
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,0.19547191663193839
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,microalbuminuria,0.1787563253348232
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,0.1787563253348232
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,0.1787563253348232
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mg,0.16364223583993814
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence,0.15812242036867172
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,0.15720618006605053
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,0.15720618006605053
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin,0.15720618006605053
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,0.2622137940647932
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological,0.18044453545579
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,0.16861984908415195
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,0.164416282600098
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative,0.15944790977053241
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,images,0.15944790977053241
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide,0.1590275061366556
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slides,0.1590275061366556
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent,0.1590275061366556
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,able,0.14558151503454625
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,2007,0.22328038742498182
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people,0.21108467436256953
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,2013,0.19729935837481
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive,0.1880263277296083
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,0.17957084268448828
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,impairment,0.17957084268448828
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,living,0.15867588037205935
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,warfarin,0.1582575122867516
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,homes,0.1582575122867516
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing,0.1582575122867516
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,0.1999471775817778
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,0.1999471775817778
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,0.18922492557674894
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted,0.17584234820078923
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes,0.16630026368981918
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,profiling,0.16097463942058574
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type,0.15541363051180254
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma,0.14214584931910182
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,separately,0.14186849933493897
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ci,0.129905682841057
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igf1,0.31975734443164827
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle,0.2072127427868733
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants,0.19255801083135493
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,atrophy,0.19255801083135493
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal,0.17627697012853855
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple,0.16879340248084726
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna,0.1553545906949088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,isoforms,0.1553545906949088
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna,0.14844434721212132
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,gene,0.142254582809595
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,0.16322889820355954
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,均p,0.15468761746096735
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,05,0.14606362083062394
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,0.14458542651540227
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,0.13893074576821032
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,0.1351874089228393
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,0.13222134404875674
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,0.13222134404875674
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,values,0.12104185026948074
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung,0.12058734256843605
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd,0.19951655766483906
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic,0.19086507867553384
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold,0.1826471623994715
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic,0.1808776791472245
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,0.1808776791472245
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tolerance,0.16906509270670353
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,4f,0.16906509270670353
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,0.16558422631338687
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetics,0.15460765533673404
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin,0.15439582689957218
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,channels,0.25535572399522893
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium,0.25009822734843123
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,0.25009822734843123
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand,0.21377485998557905
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,0.2053670860703658
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics,0.16568887194524667
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool,0.14095488952164092
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tools,0.12240467822139282
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,forest,0.11372151734190476
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel,0.10678814728266968
Machine learning: a long way from implementation in cardiovascular disease.,interests,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,statement,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,conflict,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,31911505,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,316030,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,1136,0.3065326110961704
Machine learning: a long way from implementation in cardiovascular disease.,declared,0.2806148635225926
Machine learning: a long way from implementation in cardiovascular disease.,competing,0.2806148635225926
Machine learning: a long way from implementation in cardiovascular disease.,pmid,0.24796236320596707
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,0.259525340143838
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,0.19245015869464138
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,0.16924913982663972
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential,0.14916089619682069
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,0.14916089619682069
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram,0.14916089619682069
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite,0.13654914033289087
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,83,0.1276009571436647
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,18,0.1276009571436647
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteins,0.1276009571436647
Machine Learning in Fetal Cardiology: What to Expect.,fetal,0.3272569854598894
Machine Learning in Fetal Cardiology: What to Expect.,computer,0.1799333530935289
Machine Learning in Fetal Cardiology: What to Expect.,imaging,0.17192983498061737
Machine Learning in Fetal Cardiology: What to Expect.,echocardiography,0.16471974430695044
Machine Learning in Fetal Cardiology: What to Expect.,help,0.16471974430695044
Machine Learning in Fetal Cardiology: What to Expect.,aid,0.16471974430695044
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,0.16471974430695044
Machine Learning in Fetal Cardiology: What to Expect.,perform,0.14555286399412573
Machine Learning in Fetal Cardiology: What to Expect.,ml,0.13871190830409078
Machine Learning in Fetal Cardiology: What to Expect.,cardiac,0.13740148878908617
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam,0.28432561582230265
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living,0.17289374610812133
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobeglitazone,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,label,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,odt,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld,0.17243789090598644
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,imaging,0.16476777439067344
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,0.26472135862229496
Supervised machine learning models applied to disease diagnosis and prognosis.,breast,0.2588056905507494
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,0.21794248993827303
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,0.21794248993827303
Supervised machine learning models applied to disease diagnosis and prognosis.,variables,0.20885482381050743
Supervised machine learning models applied to disease diagnosis and prognosis.,heart,0.17071587092383755
Supervised machine learning models applied to disease diagnosis and prognosis.,disease,0.16807794773230325
Supervised machine learning models applied to disease diagnosis and prognosis.,analyzing,0.16697256671744173
Supervised machine learning models applied to disease diagnosis and prognosis.,roc,0.16697256671744173
Supervised machine learning models applied to disease diagnosis and prognosis.,important,0.1639242770016221
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,0.27368277189395
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,0.20448208803559584
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,0.2042670571018558
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gαs,0.17964144038074428
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid,0.17964144038074428
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,0.17964144038074428
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,0.15367579787803748
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown,0.14493358298469713
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,0.14493358298469713
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,actions,0.14493358298469713
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ,0.283475293857309
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal,0.1860691111408882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,0.1860691111408882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inhibition,0.18286253863352436
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ,0.17033671569837996
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved,0.15041286758165115
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clp,0.1501193872820751
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",rats,0.1501193872820751
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",survival,0.14056782699923925
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",bacterial,0.13742658969827634
Innovations in pharmacological treatment of heart failure.,ace,0.2059828578930235
Innovations in pharmacological treatment of heart failure.,acei,0.17620978750124652
Innovations in pharmacological treatment of heart failure.,angiotensin,0.1752338019855529
Innovations in pharmacological treatment of heart failure.,indicated,0.16662499967107447
Innovations in pharmacological treatment of heart failure.,added,0.16662499967107447
Innovations in pharmacological treatment of heart failure.,decrease,0.15879365779072568
Innovations in pharmacological treatment of heart failure.,inhibitors,0.1517107553699735
Innovations in pharmacological treatment of heart failure.,drugs,0.14137752808020485
Innovations in pharmacological treatment of heart failure.,receptor,0.12239928218390096
Innovations in pharmacological treatment of heart failure.,31906682,0.121656794080301
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission,0.2558656963319159
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,0.2558656963319159
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,0.192338523604706
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,0.17001997151148243
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ri,0.1551775097824524
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global,0.1551775097824524
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,30,0.150109226122303
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,0.14827514293990937
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,0.1420570410882546
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,0.14095737132527056
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ,0.23119079322960995
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,0.2121057923352212
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,0.1852069943498695
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc,0.1852069943498695
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,0.17311167313355633
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,srt1720,0.17311167313355633
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,0.16954749205007996
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,0.16718520058155142
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,0.15830819636451787
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sirt1,0.15830819636451787
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,0.2517079657429678
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood,0.2517079657429678
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,0.23853683964814873
Mood disorders and increased risk of non-communicable disease in adults with HIV.,plwh,0.20389260666827103
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders,0.19295877935897937
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident,0.18665321053077777
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,0.17931213218883735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,0.17931213218883735
Mood disorders and increased risk of non-communicable disease in adults with HIV.,subhazard,0.14466789920895962
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,0.14466789920895962
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",arrhythmia,0.22157104564542066
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,0.21285664743194616
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fibrillation,0.19578891654765226
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial,0.18658687636824028
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",betahistine,0.17173140289365663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",loratadine,0.17173140289365663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish,0.17173140289365663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fractures,0.17173140289365663
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ci,0.157250448568458
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalizations,0.15721128010888125
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification,0.21204843750130792
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,0.19391532110516677
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,0.17053766813635765
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,0.17053766813635765
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,0.17053766813635765
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment,0.17053766813635765
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,0.17053766813635765
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions,0.1658865105314899
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically,0.13795244511018517
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,attribution,0.13758871685993732
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,0.22819307606529798
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,0.20485213443037897
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,0.1873344029092443
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive,0.1873344029092443
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,0.1873344029092443
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,0.18636637714556678
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,0.17524250049924395
Prediction of Left Ventricular Mechanics Using Machine Learning.,properties,0.1657103274574815
Prediction of Left Ventricular Mechanics Using Machine Learning.,kpa,0.16475011903021927
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,0.16475011903021927
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dbma,0.21708524329670317
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",σ1r,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hlox,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",flavonoid,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nds,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",mtdls,0.17514300741193792
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hbace,0.16033442884293292
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hache,0.16033442884293292
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets,0.16033442884293292
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jnk1,0.20478989663553032
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tgf,0.20478989663553032
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,fibroblasts,0.16470006495517628
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective,0.16470006495517628
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,17a,0.16470006495517628
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cmc,0.16470006495517628
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent,0.15576090483163996
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il,0.1512910378733707
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired,0.15077445131950049
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,displayed,0.13287897536989873
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,0.2527140926380536
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,0.22066543780839643
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,a1r,0.22066543780839643
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,0.20625443048656192
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,0.18861678297873927
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,0.18433831446187177
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing,0.1518526992773141
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,0.13382924567481497
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hyperpolarization,0.13382924567481497
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,0.13382924567481497
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,0.21392403438549235
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,0.21392403438549235
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical,0.20273002857289543
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced,0.18929106402129828
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,0.18929106402129828
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,0.1804607412676666
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration,0.16647089293029604
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,0.16647089293029604
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory,0.15239555339011937
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain,0.13984108594431646
Implications for REDUCE IT in clinical practice.,statin,0.2759856601161203
Implications for REDUCE IT in clinical practice.,ascvd,0.2526506986344112
Implications for REDUCE IT in clinical practice.,therapy,0.23183713222381322
Implications for REDUCE IT in clinical practice.,residual,0.20383699284008397
Implications for REDUCE IT in clinical practice.,risk,0.17351260479308078
Implications for REDUCE IT in clinical practice.,high,0.15399037201029542
Implications for REDUCE IT in clinical practice.,type,0.14793429359212004
Implications for REDUCE IT in clinical practice.,reduction,0.13575223223887303
Implications for REDUCE IT in clinical practice.,markedly,0.13150864578767685
Implications for REDUCE IT in clinical practice.,ethyl,0.13150864578767685
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization,0.2545965465156575
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,0.20475652577294814
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,0.20475652577294814
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,0.20475652577294814
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,0.20475652577294814
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,0.1874440841046745
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat,0.1874440841046745
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,group,0.17555501849789518
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,incidences,0.16519627574169035
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,occurrences,0.16519627574169035
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,0.2964412547068647
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,0.2619506363154795
Women had favourable reverse left ventricle remodelling after TAVR.,lv,0.20315356110447422
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling,0.20298853472971223
Women had favourable reverse left ventricle remodelling after TAVR.,regression,0.17815002798855695
Women had favourable reverse left ventricle remodelling after TAVR.,months,0.15648531265670185
Women had favourable reverse left ventricle remodelling after TAVR.,female,0.14440718008099374
Women had favourable reverse left ventricle remodelling after TAVR.,post,0.14430800184410583
Women had favourable reverse left ventricle remodelling after TAVR.,favourable,0.144026433143945
Women had favourable reverse left ventricle remodelling after TAVR.,greater,0.13762007130725748
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,0.26412091267719434
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,0.23567083344360554
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic,0.19854410781021262
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,0.1755054729599636
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated,0.1667836530176543
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,defects,0.16018413604591963
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,encountered,0.16018413604591963
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,0.1466768850794859
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,pcsk9,0.137030881416265
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,0.137030881416265
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,0.21335000463224693
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,0.1870193457322395
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",families,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",warts,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim,0.17212944037642974
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",manifestations,0.15757566298320522
Prime time for ticagrelor monotherapy.,21,0.4625357449779201
Prime time for ticagrelor monotherapy.,2042,0.33770812298657626
Prime time for ticagrelor monotherapy.,2032,0.33770812298657626
Prime time for ticagrelor monotherapy.,381,0.33770812298657626
Prime time for ticagrelor monotherapy.,nov,0.33770812298657626
Prime time for ticagrelor monotherapy.,engl,0.33770812298657626
Prime time for ticagrelor monotherapy.,med,0.30915444364455397
Prime time for ticagrelor monotherapy.,comment,0.30915444364455397
Prime time for ticagrelor monotherapy.,2019,0.15707916129070265
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,0.2637243826437107
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,125a,0.24992447334077808
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,0.24992447334077808
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,0.19482960936149324
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,atdc5,0.18787240690792373
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited,0.17198754036511918
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,0.17198754036511918
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory,0.16604608121594697
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,17,0.16468607386076592
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,0.15187059952734897
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",49,0.22131828164583695
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",μm,0.1767780213079064
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound,0.16636865413670135
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,0.16636865413670135
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",suggested,0.15546637243407807
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ic50,0.14700990576648956
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,0.1466222964294398
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,0.1466222964294398
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,0.1466222964294398
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",aβ,0.1466222964294398
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,0.26572744201267606
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",12c,0.25351945001616405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,0.2320840370367281
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",r5,0.23183998022143643
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound,0.21223759578555235
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds,0.17441967611445058
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,0.17441967611445058
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",x4,0.16449739615056522
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",1ug070,0.16449739615056522
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",1vb59,0.16449739615056522
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,0.2874425709662405
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,0.23308404494973023
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal,0.16520618551806823
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mice,0.15785773857687446
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",parasitemia,0.15123777870308297
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chagas,0.15123777870308297
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,0.15123777870308297
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,0.14132703634566032
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected,0.14132703634566032
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,0.13604533314789596
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,0.3014548187090477
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,0.23150437834933704
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmp,0.18618489865934287
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,0.18618489865934287
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,anti,0.18297633075859485
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,0.18297633075859485
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,1β,0.17044271322527468
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit,0.15021280392290684
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic,0.15021280392290684
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,0.1375646984522628
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,0.31474447509798487
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative,0.25312984841815284
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,0.2317273767816801
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postrasi,0.20422356786863435
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,prerasi,0.20422356786863435
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,vs,0.17373713821982792
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,surgery,0.16520186328616515
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,undergoing,0.16520186328616515
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,0.1508726555784974
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term,0.1401700291777793
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,31474577,0.34777307463832635
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,08,0.34777307463832635
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec,0.34777307463832635
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,1016,0.34777307463832635
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,002,0.3183683899976591
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,medline,0.29750543422647685
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed,0.29750543422647685
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,pmid,0.28132286851420724
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi,0.28132286851420724
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,10,0.2310552281023578
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,0.26241836988327494
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit,0.22454179479620762
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,0.22430566931322504
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",μg,0.19726427791487763
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,0.19726427791487763
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,0.19726427791487763
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,0.19726427791487763
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,0.19726427791487763
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,0.15915157734482768
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ec50,0.15915157734482768
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,0.24392920796186274
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,0.22529824528785677
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive,0.22529824528785677
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tract,0.18861179255299604
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion,0.18119368310067002
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper,0.18119368310067002
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptives,0.18119368310067002
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female,0.1666648203265581
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune,0.1550036771133597
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,0.1461859226374183
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin,0.241330155592841
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma,0.21209059741512468
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,0.2033118809389965
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated,0.1998081597472196
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,0.1856341394292908
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",activity,0.16958906068296484
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage,0.16446437553643248
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,0.16403074538588172
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cachexia,0.16403074538588172
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalization,0.16403074538588172
Sensor Networks for Aerospace Human-Machine Systems.,sensor,0.17242447920877335
Sensor Networks for Aerospace Human-Machine Systems.,systems,0.16660842992860725
Sensor Networks for Aerospace Human-Machine Systems.,operator,0.16564301744692939
Sensor Networks for Aerospace Human-Machine Systems.,aerospace,0.16564301744692939
Sensor Networks for Aerospace Human-Machine Systems.,states,0.15163767590051763
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,0.15163767590051763
Sensor Networks for Aerospace Human-Machine Systems.,sensors,0.15163767590051763
Sensor Networks for Aerospace Human-Machine Systems.,cognitive,0.1452001315933246
Sensor Networks for Aerospace Human-Machine Systems.,networks,0.13399303228399956
Sensor Networks for Aerospace Human-Machine Systems.,operations,0.13363974350293345
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,0.2630550933315484
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,0.18473991559014996
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,0.1691199054323159
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest,0.16246841269115317
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection,0.1557348350132701
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological,0.14944101994365833
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reliability,0.14873148827795232
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,0.13647886944352094
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,signals,0.13142501025635236
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,knn,0.13107849237491018
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpv2,0.33095001660853046
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular,0.30933664951364365
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,0.25896579839119976
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dystrophy,0.2487806630352801
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports,0.20071467248643063
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,ca2,0.18374397498963285
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,channel,0.17170307349354494
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent,0.13776167849994939
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic,0.12237059827926003
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors,0.11926881725699158
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,0.2555306597268642
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,0.2444502854480338
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,0.2237816826201817
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,0.21652997215749784
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,0.1980136216733737
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung,0.1805906346038866
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,frequencies,0.15941796095720712
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,subsets,0.14897116418631312
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc2,0.14049658361988315
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,recipients,0.14049658361988315
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,0.27953743958874067
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,catenin,0.26491008024324475
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt,0.26491008024324475
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian,0.2264354926189499
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pparγ,0.2264354926189499
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathway,0.19570555794774955
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,oxidative,0.17035372952366018
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,stress,0.16108747719615396
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor,0.16108747719615396
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,disruption,0.1606627506451269
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lsd1,0.29764561546630325
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,0.26550027167629403
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sox2,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,1a,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone,0.15259495832578981
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lysine,0.15259495832578981
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,0.3088539316290647
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,igf1r,0.22002186880277635
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,paraquat,0.22002186880277635
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sy5y,0.16250335643143007
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh,0.16250335643143007
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,apoptotic,0.1518543710283173
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated,0.1435943762344393
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,kinase,0.1368454690800074
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal,0.1368454690800074
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,0.1275760910003672
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,0.23456652061129846
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,0.21422079128207183
Practical guide for the use of PCSK9 inhibitors in Portugal.,pcsk9i,0.205744218655288
Practical guide for the use of PCSK9 inhibitors in Portugal.,lowering,0.1760056415358931
Practical guide for the use of PCSK9 inhibitors in Portugal.,events,0.1760056415358931
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,0.1760056415358931
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,0.16643195805918543
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,0.16643195805918543
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,0.1586096890962429
Practical guide for the use of PCSK9 inhibitors in Portugal.,practice,0.1586096890962429
